These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

74 related articles for article (PubMed ID: 7781117)

  • 21. Impact of concurrent proliferative high-risk lesions on the risk of ipsilateral breast carcinoma recurrence and contralateral breast carcinoma development in patients with ductal carcinoma in situ treated with breast-conserving therapy.
    Adepoju LJ; Symmans WF; Babiera GV; Singletary SE; Arun B; Sneige N; Pusztai L; Buchholz TA; Sahin A; Hunt KK; Meric-Bernstam F; Ross MI; Ames FC; Kuerer HM
    Cancer; 2006 Jan; 106(1):42-50. PubMed ID: 16333852
    [TBL] [Abstract][Full Text] [Related]  

  • 22. 17 beta-Hydroxysteroid dehydrogenase type 1 and type 2 in ductal carcinoma in situ and intraductal proliferative lesions of the human breast.
    Ariga N; Moriya T; Suzuki T; Kimura M; Ohuchi N; Satomi S; Sasano H
    Anticancer Res; 2000; 20(2B):1101-8. PubMed ID: 10810403
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Fine needle aspiration cytology of benign breast lumps: a review of experience with 651 cases.
    Jayaram G; Gupta M
    Malays J Pathol; 1994 Jun; 16(1):29-38. PubMed ID: 16329573
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Aspiration biopsy of mammary lesions with abundant extracellular mucinous material. Review of 43 cases with surgical follow-up.
    Ventura K; Cangiarella J; Lee I; Moreira A; Waisman J; Simsir A
    Am J Clin Pathol; 2003 Aug; 120(2):194-202. PubMed ID: 12931549
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Observations on the histopathologic diagnosis of microinvasive carcinoma of the breast.
    Prasad ML; Osborne MP; Hoda SA
    Anat Pathol; 1998; 3():209-32. PubMed ID: 10389587
    [TBL] [Abstract][Full Text] [Related]  

  • 26. The value of fine needle aspiration cytology in the diagnosis of breast proliferative lesions.
    Midulla C; Cenci M; De Iorio P; Amanti C; Vecchione A
    Anticancer Res; 1995; 15(6B):2619-22. PubMed ID: 8669835
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Inhibition of spontaneous apoptosis in human breast cancer.
    Shao Z; Jiang M; Wu J; Yu L; Han Q; Zhang T; Shen Z
    Chin Med Sci J; 1996 Dec; 11(4):200-3. PubMed ID: 9387382
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Expression of proliferating cell nuclear antigen in invasive ductal carcinoma of the breast.
    Horiguchi J; Iino Y; Takei H; Morishita Y; Nakajima T
    Jpn J Clin Oncol; 1994 Apr; 24(2):79-84. PubMed ID: 7908995
    [TBL] [Abstract][Full Text] [Related]  

  • 29. [Importance of PCNA proliferating fraction and histomorphologic prognostic factors for survival in breast cancer].
    Schönborn I; Minguillon C; Möhner M; Ebeling K
    Pathologe; 1993 Dec; 14(6):307-12. PubMed ID: 7907179
    [No Abstract]   [Full Text] [Related]  

  • 30. Breast cancer risk of lobular-based hyperplasia after biopsy: "ductal" pattern lesions.
    Page DL; Dupont WD; Rogers LW
    Cancer Detect Prev; 1986; 9(5-6):441-8. PubMed ID: 3779706
    [TBL] [Abstract][Full Text] [Related]  

  • 31. The role of fine-needle aspiration cytology and core biopsy in the diagnosis of proliferative and atypical breast lesions.
    Maygarden SJ
    Anat Pathol; 1997; 2():165-96. PubMed ID: 9575375
    [No Abstract]   [Full Text] [Related]  

  • 32. [Classification of preinvasive breast and carcinoma in situ: doubts, controversies, and proposal for new categorizations].
    Dauplat MM; Penault-Llorca F
    Bull Cancer; 2004 Dec; 91 Suppl 4():S205-10. PubMed ID: 15899609
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Tumor proliferative fraction in infiltrating duct carcinoma.
    Kesari AL; Chellam VG; Nair PP; Madhavan J; Nair P; Nair MK; Pillai MR
    Gen Diagn Pathol; 1997 Dec; 143(4):219-24. PubMed ID: 9489954
    [TBL] [Abstract][Full Text] [Related]  

  • 34. A comparison of the patterns of laminin expression in fibroadenoma, fibrocystic diseases, pre-invasive and invasive ductal breast carcinoma.
    Zheng WQ; Looi LM; Cheah PL
    Pathology; 2001 Aug; 33(3):303-6. PubMed ID: 11523929
    [TBL] [Abstract][Full Text] [Related]  

  • 35. [P21 expression of ras oncogene product in benign and malignant female mammary lesions].
    Zhang JZ; Fan SC; Liu HF
    Zhonghua Bing Li Xue Za Zhi; 1994 Oct; 23(5):302-3. PubMed ID: 7874767
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Cytologic differential diagnosis of papillary pattern in breast aspirates: correlation with histology.
    Nayar R; De Frias DV; Bourtsos EP; Sutton V; Bedrossian C
    Ann Diagn Pathol; 2001 Feb; 5(1):34-42. PubMed ID: 11172205
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Percutaneous imaging-guided core breast biopsy: 5 years' experience in a community hospital.
    Margolin FR; Leung JW; Jacobs RP; Denny SR
    AJR Am J Roentgenol; 2001 Sep; 177(3):559-64. PubMed ID: 11517047
    [TBL] [Abstract][Full Text] [Related]  

  • 38. [Diagnostic immunohistochemistry of breast epithelial lesions].
    Balaton AJ; Guinebretière JM; Penault-Llorca F
    Ann Pathol; 2003 Dec; 23(6):570-81. PubMed ID: 15094595
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Expression of c-erbB-2 in node negative breast cancer does not correlate with estrogen receptor status, predictors of hormone responsiveness, or PCNA expression.
    Kolár Z; Murray PG; Zapletalová J
    Neoplasma; 2002; 49(2):110-3. PubMed ID: 12088102
    [TBL] [Abstract][Full Text] [Related]  

  • 40. [Clinicopathologic features of cystic hypersecretory lesion of the breast].
    Bi R; Cheng Y; Yu B; Shui R; Yang W; Xu X
    Zhonghua Bing Li Xue Za Zhi; 2014 Jan; 43(1):25-9. PubMed ID: 24713245
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 4.